Shingrix Vaccine
Shingrix Vaccine is a non-live, recombinant vaccine used to prevent Herpes Zoster (shingles) and its complications, such as postherpetic neuralgia. It is primarily recommended for adults aged 50 years and older, administered in two doses. Shingrix helps strengthen the immune system to protect against reactivation of the varicella-zoster virus.
Contact us for sales assistance from our Biomedical Engineer.
Features:
-
Recombinant, Adjuvanted Vaccine: Contains a non-live antigen with adjuvant system AS01B to enhance immune response.
-
Two-Dose Regimen: Provides long-lasting protection when both doses are completed.
-
High Efficacy: Over 90% efficacy in preventing shingles and related complications.
-
Long-Term Immunity: Provides durable protection for at least 7 years post-vaccination.
-
Suitable for Older Adults: Specifically designed for individuals aged 50 years and above.
| Technical Specification |
|
|---|
- 1.0 Injection in 1 box
-
Highly Effective: Provides over 90% protection against shingles and PHN.
-
Safe for Immunocompromised Patients: As it’s non-live, it is considered safer than live vaccines in immunocompromised populations.
-
Reduced Risk of PHN: Significantly lowers the chances of developing long-term nerve pain.
-
Well-Tolerated: Side effects are generally mild and self-resolving.
-
Long-Lasting Protection: Offers sustained immunity for years post-vaccination.
